|
Congenital diaphragmatic hernia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion:</b> The signs of both systolic and diastolic altered function were observed in fetuses with CDH with s-TDI independent of the side of the hernia, and a significant positive correlation was observed between fetal cardiac systolic function and the severity of pulmonary hypoplasia.
|
31588831 |
2020 |
|
Congenital hypoplasia of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The signs of both systolic and diastolic altered function were observed in fetuses with CDH with s-TDI independent of the side of the hernia, and a significant positive correlation was observed between fetal cardiac systolic function and the severity of pulmonary hypoplasia.
|
31588831 |
2020 |
|
Atrial Fibrillation
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Measuring P-A'TDI interval identifies patients with chronic heart failure at higher risk of dying or developing atrial fibrillation during follow-up.
|
30985354 |
2019 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A near-infrared fluorescence-switchable molecule, dithienylethene-terrylenediimide (TDI-4DTE) exhibits high near-infrared fluorescence and on/off ratio, decent reversibility, and fatigue resistance upon alternating UV/vis (305/621 nm) irradiation.
|
31179680 |
2019 |
|
Chronic heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Measuring P-A'TDI interval identifies patients with chronic heart failure at higher risk of dying or developing atrial fibrillation during follow-up.
|
30985354 |
2019 |
|
Dyspnea
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The evaluation of medical history and clinical data of ALS patients showed that patients with perception of dyspnea (TDI 25.7 ± 8.0) performed significantly worse in olfactory testing compared to those who did not (TDI 30.0 ± 7.4).
|
29535673 |
2018 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Controlling for confounding factor, in male schizophrenia participants, the negative subscale score was significantly and inversely correlated with the discrimination (γ = - 0.37, p < 0.008), identification (γ = - 0.45, p < 0.008) and TDI (γ = - 0.50, p < 0.008) scores; the general psychopathology subscale score was inversely and significantly correlated with the identification (γ = - 0.47, p < 0.008) and TDI (γ = - 0.41, p < 0.008) scores.
|
29914416 |
2018 |
|
Functional tricuspid regurgitation
|
0.010 |
Biomarker
|
disease |
BEFREE |
An enlarged TA dimension was associated with outcomes irrespective of subgroups according to type or severity of TR and TDI s' (p = 0.21, p = 0.77, p = 0.15 for interaction).
|
29580628 |
2018 |
|
Intraventricular dyssynchrony
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Septal-lateral >60ms delay for the beginning of systolic velocity in TDI and septum-posterior >130ms delay in M-mode were accepted as intraventricular dyssynchrony.
|
28081851 |
2018 |
|
Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among 5801 elderly participants in the ARIC study (Atherosclerosis Risk in Communities; age range, 67-90 years; mean age, 76±5 years; 42% male; 21% black), we determined the continuous association of diastolic measures (tissue Doppler imaging [TDI] e', E/e', and left atrial size) with concomitant N-terminal pro-brain natriuretic peptide and subsequent HF hospitalization or death.
|
27927714 |
2017 |
|
Atherosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among 5801 elderly participants in the ARIC study (Atherosclerosis Risk in Communities; age range, 67-90 years; mean age, 76±5 years; 42% male; 21% black), we determined the continuous association of diastolic measures (tissue Doppler imaging [TDI] e', E/e', and left atrial size) with concomitant N-terminal pro-brain natriuretic peptide and subsequent HF hospitalization or death.
|
27927714 |
2017 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, TDI (medial E'>6.5 cm/s; lateral E'>7.8 cm/s) appears to predict LVEF recovery in patients with sinus tachycardia upon resolution of the tachycardia in patients with cancer.
|
27767228 |
2017 |
|
Sinus Tachycardia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, TDI (medial E'>6.5 cm/s; lateral E'>7.8 cm/s) appears to predict LVEF recovery in patients with sinus tachycardia upon resolution of the tachycardia in patients with cancer.
|
27767228 |
2017 |
|
Laryngopharyngeal Reflux
|
0.010 |
Biomarker
|
disease |
BEFREE |
The odor threshold, odor discrimination, odor identification, and TDI scores of the laryngopharyngeal reflux group were significantly lower than those of the control group.
|
27472044 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In conclusion, TDI (medial E'>6.5 cm/s; lateral E'>7.8 cm/s) appears to predict LVEF recovery in patients with sinus tachycardia upon resolution of the tachycardia in patients with cancer.
|
27767228 |
2017 |
|
Dermatitis, Atopic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The effect of H4R activation on NK cell migration, NK cell-dendritic cell interaction and cytokine levels in the skin was further characterized in the murine TDI model of allergic dermatitis.
|
27155791 |
2016 |
|
alpha 1-Antitrypsin Deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to measure the diameters of the Valsalva sinuses (VS), sinotubular junction (STJ), ascending aorta (AA) and aortic arch (AAr) and elastic properties of the AA (distensibility, stiffness and tissue Doppler imaging (TDI strain)) in AATD subjects.
|
22851685 |
2012 |
|
Mental Depression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TDI scores were analyzed according to complement levels (C1INH, C3, C4 and CH50), Beck depression inventory (BDI-II) and danazol treatment.
|
20649895 |
2011 |
|
Depressive disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TDI scores were analyzed according to complement levels (C1INH, C3, C4 and CH50), Beck depression inventory (BDI-II) and danazol treatment.
|
20649895 |
2011 |
|
Angioedemas, Hereditary
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Thirty patients with HAE and 30 healthy age- and sex-matched controls were evaluated for olfactory functions using the 3-stages Sniffin'-Sticks kit (threshold, discrimination, and identification [TDI]).
|
20649895 |
2011 |
|
Depressed mood
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
TDI scores were analyzed according to complement levels (C1INH, C3, C4 and CH50), Beck depression inventory (BDI-II) and danazol treatment.
|
20649895 |
2011 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We adapted template-directed dye-terminator incorporation with fluorescence polarization detection (TDI-FP) to the analysis of eight SNPs implicated in mediating the sepsis syndrome: TNF-alpha (-308), TNF-alpha (-238), TNF-beta (+250), IL-1beta (+3953), IL-6 (-174), IL-10 (-592), plasminogen activator inhibitor-1 (PAI-1 (-675)), and TLR4 299 (+1032).
|
12411588 |
2002 |
|
Systemic Inflammatory Response Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We adapted template-directed dye-terminator incorporation with fluorescence polarization detection (TDI-FP) to the analysis of eight SNPs implicated in mediating the sepsis syndrome: TNF-alpha (-308), TNF-alpha (-238), TNF-beta (+250), IL-1beta (+3953), IL-6 (-174), IL-10 (-592), plasminogen activator inhibitor-1 (PAI-1 (-675)), and TLR4 299 (+1032).
|
12411588 |
2002 |
|
Thanatophoric Dysplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The achondroplasia class of chondrodysplasias comprises the most common genetic forms of dwarfism in humans and includes achondroplasia, hypochondroplasia and thanatophoric dysplasia types I and II (TDI and TDII), which are caused by different mutations in a fibroblast growth-factor receptor FGFR3 (ref.1).
|
9069288 |
1997 |
|
Chondrodysplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The achondroplasia class of chondrodysplasias comprises the most common genetic forms of dwarfism in humans and includes achondroplasia, hypochondroplasia and thanatophoric dysplasia types I and II (TDI and TDII), which are caused by different mutations in a fibroblast growth-factor receptor FGFR3 (ref.1).
|
9069288 |
1997 |